he referenced this research in a that mrna vaccines cause uterus cancer.he fact checkers got onto this gentleman, who i behin that research, and he very plainly stated that no publications demonstrated mrna vaccines caused cancer or autoimmune disease. some of what he claimed on this research factcheck.org was able to go to the source of what he was basing those claims on, and the researcher said actually, that's not what i was saying. mark: and the very disturbing fact that a medical professional talked about a 20 fold increase in this cancer. james: whatever is going on in his clinic perhaps is an uptick in problems, but unconnected. mark: james, truth or faith. kate, always truth, never the fake. ■wwÑñ■ñ■ñ■ 8 09/22/21 09/22/21 [captioning made possible by democracy now!] amy: from new york, this is democracy now! >> to a don't support for the lifting of the illegal financial blockade imposed by the united states against cuba, which has been intensified to liberally and opportunistically during pandemic conditions, despite been condemned for decades by t

of the mrna vaccine do to immunity response and clinical effect let's look at the immune response toeutralizing antibodies so to neutralizing titers against the delta area. or for comparison it is the delta variant was 65 and 85 just concentrate on the blue one month the tighter was 241 and went up dramatically if one looks at the 65 or 85 it goes from 123 at 1479 look at clinical data. that was recently published in the new england journal of medicine from one.14 million people age 60 years and older to receive the second dose of mrna at least five months earlier. twelve days or more after the booster dose the rate of confirmed infection was lowered in the group with a factor of all 11.three and the length of severe illness was lowered by a factor of 19.five. take a closer look at that. as you can see going left to right in the days since the booster vaccination somewhere around 12 days from the third shot booster you can see an increase of protection against confirmed infection in the booster group compared with a non- booster group. what about severe disease for those aged 60 or o

this is mrna therapy. dr.obert malone, the man who pioneered this technology, said himself on multiple videos you can find throughout the interview -- the internet where he said that he would not recommend this gene therapy to be used. there were no long-term studies done so we have no way of knowing what the long-term implications are going to be. host: what would it take to get you vaccinated? i assume you're not vaccinated? caller: i am not. can i give you a few more points? my fourth point is this, there were studies done and all animal studies, the animals died because it was proven to be one of the secret ingredients of the pfizer mrna vaccine for moderna. host: that is robert this morning. this is jeff from brandywine, maryland. supports the vaccine mandate. good morning. caller: i am in support of it. i am glad president biden has taken a stronger stance. the unfortunate part with all of this is that just last year, just to remind the american people, we did not have a vaccine and the scientists got to

having the mrna vaccine is your— two doses. having the mrna vaccine is your third — two doses.se the half dose works very well, as well. it half dose works very well, as well. it has _ half dose works very well, as well. it has very— half dose works very well, as well. it has very good tolerability and is the dose — it has very good tolerability and is the dose that the manufacturers themselves are putting forward for booster— themselves are putting forward for booster vaccinations in their submissions to the ema and the fda in the _ submissions to the ema and the fda in the united states. their preferences are full dose of pfizer or a half— preferences are full dose of pfizer or a half dose of moderna as the third _ or a half dose of moderna as the third booster dose. there may be a few people — third booster dose. there may be a few people who cannot have an m nra vaccine _ few people who cannot have an m nra vaccine for _ few people who cannot have an m nra vaccine for some other reason, perhaps— vaccine for some other reason, perhaps there is an allergy. in that instance. _

a very big part of moderna's future will be in being the leading vaccine developer with mrna technology, but also additional new technology we are considering to augment that capability. i should also say within the broader pioneering context, which is where i operate, we have multiple projects as well looking to expand the security net for future pandemics. ♪ david: as we talk today we are in boston and it is probably not a surprise many people would say people from m.i.t. or harvard were involved in moderna. but your background is different than many people at m.i.t. and harvard. you did not grow up in this country, is that correct? noubar: that's right i was born in beirut, lebanon of armenian parents. lived there until the civil war in 1975, and ended up escaping the civil war and growing up in montreal, canada. david: you were a teenager when you went to canada. noubar: i was a teenager and i was extreme he fortunate. my family, they took us as political refugees. we escape lebanon. david: you went to mcgill university. what did you major in? noubar: chemical engineering. which was

on the left part of the slide, unvaccinated in red, those who had two doses of the mrna, 37, compared to those who got two doses plus the booster, down to four. this is more dramatically demonstrated on the right-hand side of the slide, when you look at the months of infection with severe disease, 175 unvaccinated, 37 of the people who got two doses, and four with those who got the boost. next slide. what about reaction is -- reactions? the kind of effects you get when you get a reaction from a vaccine question mark highlighted in yellow in this observational study, of over 1600 individuals in israel, the local and systemic reactions following the third dose was similar to those reported following the second dose, which is always more than the first dose, but quite similar following the second dose. next slide. to reiterate what dr. wilensky said, we hear about boosters, but it is still extremely important for vaccinated individuals to get vaccinated, and as dr. wilensky said, i will repeat it because it is worth repeating. after delta became the most common variant, a fully vaccinate

mrna vaccines.for a moment to your question . around mrna vaccines. those are, as you inferred, — around mrna vaccines. those are, as you inferred, a — around mrna vaccines. those are, as you inferred, a different _ you inferred, a different technoiogv _ you inferred, a different technology. and - you inferred, a different technology. and aspenl you inferred, a different. technology. and aspen is you inferred, a different _ technology. and aspen is confident that in— technology. and aspen is confident that in time — technology. and aspen is confident that in time if— technology. and aspen is confident that in time if we _ technology. and aspen is confident that in time if we were _ technology. and aspen is confident that in time if we were presented l that in time if we were presented with the — that in time if we were presented with the opportunity— that in time if we were presented with the opportunity for- that in time if we were presented with the opportunity for that - with the opportunity for

what do you think about the potential for mrna technology to be used to combat cancer and where doesneca stand on it specifically? >> in order to treat cancer in its many forms we need to have lots of new medicines across multiple scientific platforms in order to bring the therapies necessary to patients that are suffering from disease mrna represents one very exciting platform, certainly for the future there are a number of other areas that we are really focused and spending a lot of our time and energyon the anti-body drug con ju cats we're working with our partners on bringing this there have been advancements in the ability to use immuno therapies as well as other targeted therapies we know and believe having progress across all of these other different platforms in addition to mrna is going to be essential to bringing the therapies patients need across the globe. >> it's been delightful having you on our show today. thank you for coming on and sharing the positive results out of the latest trials we appreciate it david frederickson, at astrazeneca. >>> coming up on the show, eve

recovered some panelists now talk about technology mrna being used perhaps to treat cancer using themune system. one used the term holy grail to describe a vaccine that can prevent a bundle of respiratory illness, not just covid but the flu, rsv, lots of alzheimer's treatment and trials right now. i know we had fda approval and doctors seem less than enthused about that one that eli lilly is an example in the late stage trial now, human gene with all sorts of diseases and for general and is a player there. artificial intelligence being used. one of our panelists described ai like the industrial revolution brought in pharmaceuticals. >> that all sounds great to me but investors are not that excited about it. you look at most of the big pharma comedies, they are trading whale below than the average stock. >> that's right, they have two problems. the first is a have remarkably successful drugs coming off in the future. they need to replace them, investors don't trust him to do that at least not at the current levels of innovation so you have cheap companies spending off a massive amount

if people want the mrna vaccine, we will do that. we have the menu and it's available. >> what would you say to people who are tired of wearing masks and being [inaudible] ? >> well, i'm disappointed that the health office, i'm sorry that we had to go to indoor masking as well. it's the right thing to do in terms of where we are right now. especially, our projections are showing cases are going to continue to increase through this month and early september, so we really need to slow down the transmission. what i would say if you're tired of wearing a mask, if you're not vaccinated, for god's sake get vaccinated and get your family and friends vaccinated. >> had is there an now that this delta variant is surging and it is so much more contagious, a lot of those sites, they've shut down? >> so we're continuing to work with our other health partners across the city to ensure there's adequate testing for people. d.p.h. has been doing over 40% of the tests that have been administered. so just to emphasize that piece working with kaiser an

that cell produces an enzyme, an ingredient used to make mrna vaccines.he program for them makes the ingredient 10 times more efficiently than the previous version. that is a way to hopefully expand the volume of vaccine production and lower cost. that is a program in the space. to give you another example, we shifted a couple of weeks before that to crone outside a canada. that is engineered yeast to produce cannabanoids. so two very different applications. >> mrna vaccines are on the mind. continuing vaccine hesitancy. now, a lot of booster confusion. this new decision is adding more confusion into the equation. how is this going to play out? are we never going to return immunity because it there is never going to be full clarity? >> i think that at the right of delta, we will not reach herd immunity anyway. -- the infectiousness rate of delta, we will not reach herd immunity way. the goal is to reduce mortality. we will not get rid of this. it will end up being endemic, like the flu. the problem is that delta variant spreads kind of like a chicken for

>> so one of the first hubs -- the first global hub to be established for mrna research. was established as part of the initiative from the wto and after a robust call for interest -- south africa was chosen as the first of these hubs. mrna technology was the chosen technology because it lends itself to that scaling up of manufacturing. this is what is called an mrna hub, but we might move to more technologies and the wto can speak to that with more eloquence. the challenge we have is the late stage technology, the proven technology -- which at this stage pfizer and moderna has decided not to cooperate with the wto in supporting the hubs through technology transfer -- in this delays the process, which means south africa will either have to use unproven technology or mrna technology -- the ide with this hub is it will become a training hub. companies involved which are both located in cape town, when would be investing in training, the first south african company that was distributed, but also be able to train other hubs across africa. as we heard from some yesterday, be a

mrna vaccines are our insurance against variants and production failures and our most hopeful way tohe world through this disaster. william: i want to get back to the pharmaceutical companies and a second, but back to the president. too little too late, what do you want him to be doing? >> credit where credit is due. the u.s. is donating hundreds of millions ofoses, they are accelerating the schedule. they are funding the delivery of vaccines, education administration programs, not just dumping them and hoping it will work out. that is very important. the real challenge is that there are too few doses being produced. we are likely to have a real shortage of the most effective vaccines through 2022 and because of that, we will have more risk of dangerous variants, slower recovery of travel and trade, more political instability, and millions of lives lost that could be saved. william: in the past, you have been critical of the pharmaceutical companies. you said, people are dying because of the choices of my dharna -- moderna and pfizer. what are the things they could do to speed this e

someone's mrna doses, johnson & johnson, and down the list. then they sit in a warehouse and are not applied to people. that has to be improved. the task force is urging the advanced economies to allow a swapping of doses. they have it scheduled into their warehouses in all over of this year, november of this year, allowing that dose to go to a developing country person and take a later delivery schedule. you don't need it, you have access doses. >> an excellent point, we are having a conversation about who stirs. many people say there are yet to receive the initial dose. do you need the biden administration to take more leadership? >> i think the world has to come together and find solutions to this problem. countries are going to want to do that as needed in order to protect their population. that still leaves huge amount of access doses. what we are working on is try to get november and december deliveries scheduled so that countries prepared to deliver that kind -- you need a specific cold storage, or personnel on each kind of vaccine. tha

that might be two doses of a j&j, but for the mrna, we know from studies that are already ongoing inhen the degree of attention against infection or severe disease goes down to a certain precarious level, when you give the person that third boost, you dramatically increase the level of protection. even more so than before the boost. it goes up to and beyond the level of protection. i mean, i believe strongly that ultimately we're going to see that as proper regimen, three doses of an mrna. >> the third dose makes you more protected. trouble has been some mixed messaging, movement of the time line on when that third dose will be fully approved. i know you have said that you still believe by the week of september 20th or close that the white house will be able to move forward on its plan for booster shots, but governors, understandably frustrated about some of this guidance. have a listen, i want to get your reaction. >> we've got people that are well beyond six months that are 60 and older, that need the booster shot, and we can't give it to them because we're being held up by, you kn

went forward, we started realizing that there was actually a path that we could point to make this mrna molecule. once we get to the stage where it's clear that there is some intellectual property there, that's when we say how are we going to create 18 to lead it. david: the company has a market value of 190 less billion dollars. you first invested, how much money did you put into moderna? >> we capitalized the fertile -- the first couple of years. we had about $11 million over a couple of years. david: $11 million has had a return of infinite amount? >> no? -- no. david: when moderna was coming up with the vaccine that helped with the pandemic, what did the ceo say? >> when the beginnings of the pandemic were beginning to show themselves, back in 2020 we have a discussion about starting a program just to be in a position in case they get serious. the reason was not because of the pandemic. nobody was using that word. we thought we would have an opportunity to demonstrate one of the advantages of our platform. speed of execution, speed of design. speed is -- speed it takes a long time a

a very big part of moderna's future will be in being the leading vexing developer with mrna technology, but also additional new technology we are considering to augment that capability. ♪ david: as we talk today, we are in boston and it probably is not a surprise many people would say from an i.t. harvard were involved in moderna --mit or harvard were involved moderna moderna in involved in -- involved in moderna. your background is different than many people from m.i.t. and harvard. >> i was born in beirut of armenian parents. it lived there until the civil war in 1975 and ended up escaping and growing up in canada. david: you were a teenager when you went to canada. >> i was a teenager and i was extreme -- extremely fortunate. my family, they took us as political refugees. we escaped lebanon. david: you went to mcgill university. what did you major in? >> chemical engineering. it was an interesting field at the time because that is a field that first got drawn into biotechnology when that industry started. david: after you graduated, you went to m.i.t.? >> yes, i was a first graduate

as far as, for instance, the cold chain that is needed for the mrna vaccines, this does supply a more viable option for a lot of other countries. it is still a very important vaccine. again, there are some people who for whatever reason either have side effects or personal objection to the mrna vaccine. i think johnson & johnson should move ahead. >> we had kinda forgotten that one of the benefits for johnson & johnson is that it does not need the supercold refrigeration and so that makes it easier to send and distribute throughout the world, really. i do want to ask you, though, for the folks who did already get the johnson & johnson and there are 50 million people in the country who did, what is the recommendation to them now? should they be getting a pfizer or moderna shot as quote unquote a booster. san francisco january allow that. some people are going ahead with it. what would you advise? >> so, locally, i agree with what san francisco is doing. , providing a second dose just to boost people's immunity up to the higher level. there is not an official recommendation, but again a

and then the combination of hesitancy because of the astrazeneca situation and then delays getting mrnamic. there is a lot more on the website about continue in corona virus stories, not least the story thatjohn has just been telling us about that brazil argentina match and the bizarre circumstances under which it had to be abandoned. thanks for being with a seven bbc news. now it's time for a look at the weather with louise. for most of the day of welcome sunshine and warmth, with temperatures we haven't seen since july. there will be some cloud and temperatures heavy for a time because the far north and west and this is the radar picture throughout the afternoon affecting the far north and west of scotland and northern ireland. some of that heavy at times but welcome rain here. some of the areas have got water restrictions due to the lack of summer rainfall. now, that the weather front will continue to drift its way south out of the borders and we can all the time. it is the dividing line between more cloud through the night to the north of that but we could see some patchy mist and f

> we think if we don't have any protection with the vaccine, for example, if we need to wait until mrnavailable in our country, it's more we will have been facing a problem worse than the condition. at least there is still protection. >> the united states will purchase a half a billion doses. >> schifrin: but sinovac's lower efficacy created a diplomatic opening. in june, the u.s. donated 500 million doses to covax, including the million to indonesia. last month, dr. irawany received a moderna booster. others have received pfizer. >> schifrin: but vaccine diplomacy remains a competition. last month, on her first trip to southeast asia, vice president kamala harris planned to announce the u.s. would donate one million vaccines to vietnam. but during a three-hour flight delay, china stepped in and announced it would donate two million of i own vaccines. and today, most of indonesia still only has access to sinovac. >> schifrin: the vaccine competition continued this week. yesterday, chinese president xi jinping promised to export another one billion vaccine doses this year. >> schifrin: t

couple of weeks ago we already had the for any individual immune compromised who received one of the mrna vaccines are eligible for a booster. right now if you're 18 to 65 with a condition that places you at a severe risk for covid-19 or you work in a setting that could place you at higher risk, you are a candidate for a booster. but again, just for pfizer not for moderna yet or j&j that data is a couple weeks away in terms of their authorization for boosters as well as mixing and matching that's what we're interested in learning is it better to mix and match and do an mrna following an j&j or mixing and matching the mrna. >> let's talk about the shortage of antibody treatments nationwide this is apparently quite the problem in a lot of places it's reached the point where the biden administration has had to cap the number of treatments states can get states with populations like kentucky feeling the effect of it with hospitals filling up some creating tents in parking lots how big of a deal is this shortage >> it's a big deal practically and philosophically. first of all, the need for the

on the left part of the slide unvaccinated in red those who have two doses of the mrna, 37, comparedt two doses plus the booster down to 4. this is more dramatically demonstrated on the right-hand side part of the slide. when you look at the months of infection with severe disease, 175 unvaccinated, 37 of the people who got two doses and 4 with those who got the third boost. next slide. what about the kinds of effects you get when you get an injection of a vaccine? as shown highlighted in yellow in this observational study of over 1,600 individuals, again in israel, the local and systemic reactions following the third dose was similar to those reported following the second dose which is always more than the first dose but quite similar following the second dose. next slide, to reiterate what dr. walensky said, we're talking about boosters but the fact is it's still extremely important for the unvaccinated individuals to get vaccinated. as dr. walensky said, i will repeat it because it's worth repeating, after delta became the most common variant a fully vaccinated person had a reduce

i mean, there are a handful of studies that have all showed the same thing, which is two doses of mrna vaccines are highly effective in preventing severe disease including delta and including all age groups so we weren't as -- felt as compelled to follow israel's lead and rather we wanted to test the water with one foot by putting the vaccine into people who are older, those greater than 65 or those with high risk medical conditions and then learn from that. remember, the initial phase 3 trials of the mrna vaccines were in 30,000 for moderna. 44,000 people for pfizer. the phase 3 trial for three doses was in 306 people so i think we really do need to test the water with one foot as we move forward. >> so there were some dramatic twists, so to speak, as far as these panels go. you voted unanimously eventually to limit the scope as you mentioned recommending booster shots for those 65 and older and at high risk. what was different about that group specifically and then what's your advice for those people who could soon be eligible? >> right, i think also again as we said in the prelimina

and to that i say, look, the mrna vaccines were never intended to vaccinate the world with a brand-newu just cannot make enough of it and that's why where our vaccine comes in, a low cost similar levels of protection, easily accessible vaccine that there's no limit to the amount you can scale and so we've been frustrated not having more help from the u.s. government and the international bodies on our own, we've been scaling up production with biological e, an amazing organization in india and bio pharma in indonesia, but that's the answer that we cannot rely exclusively on mrna vaccines, if we do that we are not going to vaccinate the world until 2023 or later. >> i was struck by something in the fda commissioner's statement last night when we were talk being who would potentially be eligible here, the idea of 65 plus and the vulnerable, but that could be because you're sick or because of your job, they talk about people who are health care workers, teachers, day care staff, grocery workers, homeless shelters, prisons, among others. is this third shot if and when it's authorized -- to

the mrna technology is not a new technology, right?ng that has been worked on for a while. maybe -- covid -- covid-19 vaccine, right, because it's novel, was a novel virus, it's new. but the technology through which this was developed is not something that was developed overnight. >> well, there is two pieces to this. first of all, you know, we have been working on coronavirus vaccines for over a decade and our group and others were able to determine that the spike protein is the target -- the appropriate target of the vaccine. how you deliver the spike protein. how you induce virus-neutralizing antibodies. so right off the bat, that's a decade of research that -- that went into this which is a timeframe that goes along with other vaccines. and then, you have the fact that the discovery that mrna can induce an immune response. that discovery's made in 1961. so, this builds on decades of research. i think part of the problem, don, was when the ceos released their press releases. you know, when they are sending out a press release, they'

three doses of an mrna. gl . >> let's talk about this now, cnn chief medical correspondent dr. sanjay gupta. what do you think about what you heard there from dr. fauci? >> i'm glad he's phrasing it that way. it's an important message. and obviously he's dr. fauci, he's sort of, you know, relying on decades of judgment when it comes to something like this as well. i think one of the things is that we were told all along. look at some point we might need boosters. why would we need boosters, if we see the vaccines aren't working as well. pull up the graphic to show you what dr. fauci was talking about, how well the vaccines do work. you can see it's hard to make out. the top lines that are flat, those are younger age groups, and you can see there's no drop off in terms of jooverall effectiveness. where you see the drop off, people who are older, 75 years or older. boosters will be necessary for certain segments of the population, such as people who are older, based on that graphic. what we're now hearing from dr. fauci and lots of others, boosters are always going to be part of

right, for the mrna vaccines, pfizer _ that right?t? right, for the mrna vaccines, pfizer or maternal. it | vaccines, pfizer or maternal. it sounds like a bit of a compromise but this is the first i'm hearing of that decision. one dose of the mrna vaccines is not highly effective against the delta variant, and since the delta variant has become prominent, it is really a whole new ball game. so again, it sounds like a bit of a compromise was not maybe they are trying to conserve a scarce resource, i'm not sure.— resource, i'm not sure. yeah, it sounds a _ resource, i'm not sure. yeah, it sounds a bit _ resource, i'm not sure. yeah, it sounds a bit odd, _ resource, i'm not sure. yeah, it sounds a bit odd, that, - resource, i'm not sure. yeah, it sounds a bit odd, that, though, j sounds a bit odd, that, though, doesn't it? we are saying it is for moderate use for most 12 to 15—year—olds, healthy children, and yet we are not giving them enough dose to make a real difference. that will confuse people. it dose to make a real difference. tha

nuzzo: i reject our mrna vaccines are not appropriate for the rest of the world.potentially being used. people worry about cold temperatures. we are learning more about the stability echo temperatures. africa has proven its ability to maintain a cold chain. we need to start doing more with the vaccines we have to improve access. i think there are other vaccine candidates on the horizon that will add to it. we need more vaccines and we have right now. i will take them all, absolutely. tom: i look will be art and it's about the booster. one of my going to get a booster? is a booster upon us? dr. nuzzo: my guess is that if the fda committee endorses anything, it may be boosters over the age of 65. i think that might be next offering. we will see. the president is eager to push these but we need to let the scientists evaluate the data. not to distract from our topline mission which is to get first and second vaccines and arms. jonathan: got to leave it there. dr. jennifer nuzza. i think most people are confused about the booster. should they go and get one or not? wai

here's why we're not going to get here with mrna vaccines because you just can't make enough of themriod of time. it's a brand-new technology. here's the plan. and nobody really wants to arti articulate here's the plan. what we've recommended to them is we've got a simple, low cost vaccine that's now being scaled for 100 million doses in india. submitted our first developed in our texas center for vaccine development. indonesia is making another prototype version of the vaccine. this is something, there's no limit to the amount you could scale. we would like the g-7 countries, including the u.s., to take ownership on that and start producing it. it has no patent on it, and we could quickly vaccinate the world. for some reason, no one wants to articulate the problem and second, everybody's so fixed in their head on mrna vaccines, which we're just not going to be able to make enough over the next year. >> let me ask you about something you tweeted. the start of fall today. 10,000 americans died over the summer of covid. you tweeted this, death by anti-science aggression. defiance of va

this data says that even after the second full dose of the mrna vaccine, moderna or pfizer, that afterer of months, the immune protection starts to wane and drop. we are worried about that. i think that tony fauci is saying something that is entirely valid. that is, let's get ahead of. this let's not wait for people who have been immune to become non immune. that means let's give a big boost right now, or as soon as we can, to everybody that has been two dose immunized to date. the moral dilemma here is that, we talked about this before, the world health organization, w.h.o., is also very concerned that we are indulging ourselves. in having a third dose. when there are so many countries that do not have a vaccine to vaccinate one or two of the percent of the population. but i think the scientific validity -- our >> guest tonight, irwin redlener, thank you for our time or for taking our questions. coming up for, us as for tonight, it's more difficult for many texans to vote. full stop. we will ask susan glasser and peter baker what happens now. r what happens now hey, i just got a text

35,000 participants followed, there were no obvious safety signals among pregnant women who received mrna covid-19 vaccine. if you look at the immunogenicity in pregnant and lactating women, you see potent antibody and t-cell responses as well as cross-reactive immune response against the number of variants. if you look at breast milk, another advantage of getting a pregnant woman vaccinated, when that woman breast-feeds it passes immunization, specific antibodies in breast milk that were seen in a study with a six week follow-up period. again antibodies found in breast , milk show strong neutralization of the virus, protecting your newborn baby. if you look at the strong statement of 23 leading organizations that urged all pregnant individuals and recently pregnant, planning to become pregnant, or lactating and other eligible individuals to be vaccinated, the bottom line is to get vaccinated. back to you, jeff. jeff: let's open it up for a few questions. >> we will go to tbs. >> i have a question about the worries you have with back to school children. is there anything you are seeing gi

do we care about the tighter concentration in the systems of mrna virology vaccines? dr.: we care about the antibodies that are produced in response to the vaccination, whether that be the mrna vaccine or the other vaccine. there are two types. we do not know right now what is the critical amount of antibodies needed to prevent you from getting, transmitting covid to others. we do know that those anti-bodies, titer, go down over time, and the lower your antibiotic titer, the less likely you are -- more likely you are to get sick with covid. tom: i guess we are on schedule with boosters. there seems to be trepidation. what you say for people who say wait, one-shot, to shot, why do i need a booster? dr. hansoti: you absolutely will need a booster. the question has never been -- what we need a booster? the virus changes, mutates over time, as we know, boosters are necessary. the question is -- when do we need a booster? when you have a global supply chain shortage, should we be prioritizing boosters or unvaccinated individuals? who should be getting boosters and what the dos

right now we know that two doses of mrna are highly effective and the cdc made that statement.gotten two doses of mrna vaccine and you are a member of the general population and aren't in these other high-risk groups, consider yourself fully vaccinated because i think the message inadvertently sent by president biden when he said basically three doses for all was that you aren't protected at two doses which isn't true. >> what would you tell anybody out there in one of the vulnerable groups that walensky said should get the shot, including frontline health care workers or whatever and they're still kind of confused or weary of getting the booster because there was this competing guidance when it came to their group? >> right. i think what we're going to say is, for example, in our hospitals is that you can get a third dose if you like. i don't think certainly we're going to make it part of any sort of mandate, and that was a good thing about the cdc statement when they said two doses good enough for the general population because for places with mandates, what does it mean to b

of cause for concern, with data from israel that says that even after the second full dose of the mrnacine, moderna or pfizer, after some number of months, protection starts to drop. and we're worried about that. and i think that tony fauci is saying something that is entirely valid. let's get ahead of this. let's not wait for people to become non-immune. let's give a big boost right now, or as soon as we can to everybody that has been two-dose immunized to date. the dilemma is, the world health organization is also very concerned that we're indulging ourselves in a third dose when there are so many countries around the world that don't have enough vaccine. we have a lot of variables to weigh. but i think the scientific validity of what fauci was saying is -- >> doctor, thank you very much as always for your time and for taking our questions. >>> coming up for us, as of tonight, it's more difficult for many texans to vote. full stop. we'll ask susan glasser and peter baker what happens now. earn at the end of their first year automatically woo! i got my mo-ney! it's hard to contain you

question to the advisory committee about whether we would endorse a third booster dose of the pfizer mrna of age and up that question received a majority of no as votes. i think around a margin of 17 no to 4 yes and then the question got rephrased. we partnered with fda to rephrase the question for 65 years of age and up, and other individuals at risk for severe covid and that passed overwhelmingly as a yes. >> you know, there were, of course, some people that thought that was the wrong decision. why right now are for most of americans a lower risk group under the age of 65, don't have some kind of serious como comorbidity, why is that the right decision now, doctor >> as we make these decisions, look, the fact is that vaccines you're giving to healthy people. so safety has to come first. there simply wasn't a lot of safety data presented to us by the sponsor. in this case pfizer. for the younger age groups particularly in populations here in the united states we anticipate, as more data come available in the coming weeks and months, that this question about third booster doses for the pf

the move to produce an mrna job comes as concerns grow over vaccines.e studies show that the enactive vaccines create fewer antibodies than mrna shots. singapore is forming a digital bank. a british lender will invest 170 u.s. million dollars -- hundred 70 million u.s. dollars. they will put in $71.5 million for the remainder. it is charters second digital business in the region. >> we are seeing a researcher japanese equities adding to what we have seen over the last couple of days. the nikkei back above the 30,000 level held by the inclusion of some of these big names from next month. look at those. we have nintendo. nintendo was largely expected. our stocks reporter joins us. this is a reshuffle. it happens often. a lot of people -- what are people saying about these changes? reporter: like you said, we have nintendo included the strand. and nintendo was somewhat expected. the inclusion of the other two were less expected but overall investors are welcoming the change. like you said, these are big companies with big market cap and these are very popu

look back on it months from now, will be that three doses is really what you should be getting of an mrnaare going to see that as the proper regimen. three doses of an mrna. >> the administration is still targeting the week of september 20th for the third dose of the pfizer vaccine to roll out with moderna shortly after. some 70 million americans still have not even received one dose of the vaccine. and those are of those eligible. the urgency couldn't be more clear with the delta variant rampant. experts are worrying the school year will lead to a cascade of new cases in schools. let's bring in someone bearing the burden. nurse manager at valley weiss health medical center, and also a professor at vanderbilt university medical center. doctor, first new cases nationwide were three times higher. and last year 31 states saw a surge in cases a couple weeks after the holiday weekend. are we going to see that again? >> well, i think we're all concerned about that. the curve is going up. and indeed, the activities over the holiday weekend could drive it even higher. we're concerned about that.

anthony fauci says he believes three doses of an mrna covid vaccine like pfizer or moderna will becomethe norm at some poi the white house is still aiming for a september 20 timeline to begin rolling out booster shots, but found she says we need to do more to convince millions of unvaccinated americans to skip the first shot. >> when you give the person the third boost, you dramatically increase the level of protection even more so than before the boosting goes up to and beyond the level of protection. so i believe strongly that ultimately we are going to see that as the proper regimen, three doses of an mrna. we have 75 million people in this country who are eligible to be vaccinated and who are not yet vaccinated. if we get the overwhelming majority of those people vaccinated, we can turn this around. larry: except, we are not turning around now. the numbers are not looking great. california's top doctors are concerned about a possible fifth wave following a busy labor day weekend. >> this is not the time to throw up your arms and dance for joy that this is gone. it isn't. it is goin

but people who get the disease, if they've gotten two mrna doses, they're not dying. not going on ventilators. they're not getting very sick. so the vaccine's doing what it wants, but it did provide an opening for people to look at other treatments. and you know, they've come up with some incredible ones, from bleach to hydroxychloroquine, to this, which is actually a horse deworming. >> dr. anthony fauci says dramatic data coming from israeli studies support the case for covid boosters. you mentioned this third shot. what is your view on when people should be getting that third shot? >> you know, i'm very sorry to hear and feel this kind of conflict between taking the doses that we have and sending them to country that is have had no doses versus vaccinating at home, people who need that third dose. and i don't think we should be in conflict. we have a number of senior citizens over 65 who are immunocompromised, who perhaps haven't had their dose in eight months. they should certainly get a third dose. but after that, i wish we would pause and look at the data and th

you know the difference between mrna vaccines between the j&j vaccine? interviewed robert malone. he actually has been saying natural immunity is better than the mrna -- he founded it for the moderna vaccines. shouldn't we listen to his science? research monoclonal antibodies like regeneron, and god forbid you contract covid, vaccinated or breakthrough case and you are fully vaccinated and you still test positive, research the therapeutics if you contract covid. but again, ask your doctor. talk to the people that went too medical school. whether it's a breakthrough case, you're fully vaccinated or unvaccinated. i went every american to stay healthy.h in other words, educate yourself. what medical school did humpty dumpty go to? or any of these other fake news, cnn commentators. where did they go? their one-size-fits-all medicine for all the other tv commentators? did they go to medical school? i said over and over again, i believe in science.en as a matter of fact, i did a whole special on face transplants and hand transplants. i've been in operating roo

shery: does that mean those mrna vaccines are now more available to those countries?eason the chinese vaccines were used, even though they were not as effective, right? >> there were two things going on early in the pandemic. number one, any fracturing just wasn't fully -- manufacturing just wasn't fully ramped up yet. early on, the manufacturing just wasn't as great as it is now. there was also the other element of the entire world being unvaccinated. you had countries like the u.s. and the u.k. in many places in europe that were keeping all the vaccine that it was producing. we saw the same thing in india. while there was production happening, those charts were not able to get to some of these other places, specifically developing countries and places that couldn't pay as much or perhaps were relying on covax donations. they just didn't come in and the early days. china stepped up then. we should note the vaccines are very effective from china, reducing hospitalizations and deaths. we are talking about the continuing infection rate here. shery: michelle cortez, with